Business
Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
Guy Cipriani brings over 17 years of biotech and pharma business development experience to his role as Senior Vice President and Chief Business Officer of
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"Guy Cipriani brings over 17 years of biotech and pharma business development experience to his role as Senior Vice President and Chief Business Officer of Aethlon\n Steven LaRosa, M.D., with over 20 years of experience as a practicing physician and infectious disease specialist, joins as Chief Medical Officer of Aethlon\n\n\nSAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy Cipriani as Senior Vice President and Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer. In his new role, Mr. Cipriani will oversee business development and partnerships, while also contributing to fundraising and corporate development. Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier®, including leading clinical operations and regulatory strategy.\n\"The appointments of Guy and Steve enhance the breadth of experience and practical clinical and business experience of our existing leadership team,\" said Charles J. Fisher, Jr., M.D., Chief Executive Officer of Aethlon. \"Guy brings a remarkable scope of accomplishments and experience to Aethlon, including partnering, strategy, licensing, and intellectual property development. Steve has a unique blend of clinical leadership and industry research experience to take the helm of our clinical development programs as we continue to validate the Hemopurifier in cancer and infectious diseases.\"\nMr. Cipriani has served on Aethlon's Board of Directors since June 2018. Prior to joining Aethlon as an executive, he served as the Chief Business Officer at Microbion Corporation, a company focused on the development of a new class of antibiotic therapies for difficult to treat and resistant infections. His business and corporate development responsibilities at Microbion included securing partnerships and raising dilutive and non-dilutive capital for the company's promising clinical-stage pipeline. Prior to Microbion, he served as VP of Business Development at Cascadian Therapeutics where he was responsible for licensing-in several promising pipeline candidates and generating external interest in the company's clinical-stage pipeline to ...